Navacaprant

Navacaprant
Clinical data
Other names	BTRX-140; CYM-53093; NMRA-140; NMRA-335140
Identifiers
	IUPAC name 1-[6-ethyl-8-fluoro-4-methyl-3-(3-methyl-1,2,4-oxadiazol-5-yl)quinolin-2-yl]-N-(oxan-4-yl)piperidin-4-amine;
CAS Number	2244614-14-8;
PubChem CID	137434175;
ChemSpider	78316413;
UNII	XK5ILZ28KI;
KEGG	D12869;
Chemical and physical data
Formula	C25H32FN5O2
Molar mass	453.562 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CCC1=CC2=C(C(=C(N=C2C(=C1)F)N3CCC(CC3)NC4CCOCC4)C5=NC(=NO5)C)C;
	InChI InChI=1S/C25H32FN5O2/c1-4-17-13-20-15(2)22(25-27-16(3)30-33-25)24(29-23(20)21(26)14-17)31-9-5-18(6-10-31)28-19-7-11-32-12-8-19/h13-14,18-19,28H,4-12H2,1-3H3; Key:CQOJHAJWCDJEAT-UHFFFAOYSA-N;

Navacaprant (developmental code names include BTRX-335140, BTRX-140, CYM-53093, NMRA-335140, and NMRA-140) is a selective κ-opioid receptor antagonist which is under development for the treatment of major depressive disorder and bipolar depression. It was originated by BlackThorn Therapeutics and is being developed by Neumora Therapeutics. As of February 2025, navacaprant is in phase 3 clinical trials for major depressive disorder. In January 2025, it was disclosed that navacaprant had failed to show effectiveness for major depressive disorder in a phase 3 trial. Upon this announcement, the stock price of Neumora Therapeutics decreased by 80%.